Photodynamic therapy with 3-(1'-hexyloxyethyl) pyropheophorbide-a for early-stage cancer of the larynx: Phase Ib study.
BACKGROUND
The purpose of this study was for us to report results regarding the safety of 3-(1'-hexyloxyethyl) pyropheophorbide-a (HPPH) mediated photodynamic therapy (PDT) in early laryngeal disease, and offer preliminary information on treatment responses.


METHODS
A single-institution, phase Ib, open label, noncomparative study of HPPH-PDT in patients with high-risk dysplasia, carcinoma in situ, and T1 squamous cell carcinoma (SCC) of the larynx. The primary outcomes were safety and maximum tolerated dose (MTD), and the secondary outcome was response.


RESULTS
Twenty-nine patients and 30 lesions were treated. The most common adverse event (AE) was transient hoarseness of voice. Severe edema, requiring tracheostomy, was the most serious AE, which occurred in 2 patients within several hours of therapy. The MTD was 100 J/cm(2) . Patients with T1 SCC seemed to have good complete response rate (82%) to HPPH-PDT at MTD.


CONCLUSION
HPPH-PDT can be safely used to treat early-stage laryngeal cancer, with potential efficacy. © 2015 The Authors Head & Neck Published by Wiley Periodicals, Inc. Head Neck 38: E377-E383, 2016.
['Shafirstein|Gal|G|', 'Rigual|Nestor R|NR|', 'Arshad|Hassan|H|', 'Cooper|Michele T|MT|', 'Bellnier|David A|DA|', 'Wilding|Gregory|G|', 'Tan|Wei|W|', 'Merzianu|Mihai|M|', 'Henderson|Barbara W|BW|']
D000328:Adult D000368:Aged D000369:Aged, 80 and over D002278:Carcinoma in Situ D002294:Carcinoma, Squamous Cell D005260:Female D006801:Humans D007822:Laryngeal Neoplasms D008297:Male D008875:Middle Aged D010778:Photochemotherapy D017319:Photosensitizing Agents
photodynamic therapy larynx dysplasia carcinoma in situ squamous cell carcinoma